on GENSIGHT BIOLOGICS S.A. (EPA:SIGHT)
GenSight Biologics Reports EGM Results
GenSight Biologics, a biopharmaceutical company based in Paris, announced the outcomes of its Extraordinary General Meeting held on January 28, 2026. All proposed resolutions were approved except the 8th, which concerned a reserved capital increase and was rejected by shareholders.
The approval of key financial authorizations ensures that the company retains the financial flexibility essential for pursuing its strategy. Deputy CEO and CFO, Jan Eryk Umiastowski, chaired the meeting, addressing questions from shareholders and providing clarifications as needed.
The rejection of the 8th resolution does not impact the company's capacity to handle future capital transactions. Detailed results of the vote and a meeting replay are available on GenSight’s website.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all GENSIGHT BIOLOGICS S.A. news